Skip to content
OpenCapital
Get started

MoonLake Immunotherapeutics MLTX Cash & Equivalents

Cash & Equivalents at other companies

Eli Lilly logo
Eli LillyLLY
$5.28B+70.8%
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$49.52M-40.7%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$248.47M+152%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$5.7M-20.0%
Aurinia Pharmaceuticals logo
Aurinia PharmaceuticalsAUPH
$41.01M-38.3%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$144.09M+60.2%

Other financials

Income statement

See full
Operating income-$70.0M-47.5%
Net income-$69.7M-74.5%
EPS (diluted)-$0.98-55.6%

Balance sheet

See full
Total debt$100.8M+33.3%
Total equity$254.0M-37.7%
Total assets$400.4M-21.7%

Cash flow

See full
Operating cash flow-$66.3M-73.8%
CapEx--100%
Free cash flow-$66.3M-73.6%

Valuation

See full
Market cap$1.56B-45.9%
Enterprise value$1.36B-50.0%

Returns & leverage

See full
Return on equity-77.7%-221pp
Debt / equity0.4×+0.2×
Current ratio8.6×-12.5×

Where this comes from

Reported directly by MoonLake Immunotherapeutics in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents.

The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about MoonLake Immunotherapeutics's cash & equivalents.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MoonLake Immunotherapeutics's cash & equivalents?
MoonLake Immunotherapeutics (MLTX) reported cash & equivalents of $298.49M in Q1 2026.
How has MoonLake Immunotherapeutics's cash & equivalents changed year-over-year?
MoonLake Immunotherapeutics's cash & equivalents increased by 9.9% year-over-year, from $271.6M to $298.49M.
What is the long-term trend for MoonLake Immunotherapeutics's cash & equivalents?
Over 5 years (2020 to 2025), MoonLake Immunotherapeutics's cash & equivalents has grown at a 203.5% compound annual growth rate (CAGR), from $1.3M to $334.52M.
What does cash & equivalents mean?
Cash on hand plus highly liquid investments with maturities of three months or less at purchase — treasury bills, money market funds, and commercial paper.